Home » 483: Stason Inspection Reveals Inadequate Investigations
483: Stason Inspection Reveals Inadequate Investigations
In a recent Form 483 handed to Irvine, Calif.-based Stason Pharmaceuticals, the FDA makes seven observations, including calling the company’s investigations into batch noncomformances “inadequate.”
Drug GMP Report
Drug GMP Report
Upcoming Events
-
23Apr
-
25Apr
-
07May
-
14May
-
30May